Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) filed its Monthly Return for Equity Issuer for the period ended 31 March 2026, showing no changes to either authorised or issued share capital.

Authorised / registered capital • Total authorised share capital stood at RMB 243.42 million, unchanged from February. • Structure: 235.70 million H shares and 7.71 million unlisted foreign shares, all at a par value of RMB 1 per share.

Issued share capital and public float • Issued H shares (HKEX: 02185) remained at 235.70 million; no treasury shares were held or cancelled during the month. • Issued unlisted foreign shares were stable at 7.71 million. • Bio-heart confirmed that its public float continues to meet the Main Board’s minimum 25% free-float requirement.

Capital instruments and other movements • The company reported no outstanding or newly issued share options, warrants, convertible securities or other equity-linked instruments. • No share repurchases, cancellations, redemptions or treasury-share transactions occurred during March.

Corporate governance • The monthly return was signed by Executive Director and Joint Company Secretary Ms. Wang Yuqing on 8 April 2026, fulfilling HKEX disclosure obligations under Listing Rule 13.25B.

The absence of equity movements underscores a period of capital stability for Bio-heart, with its share structure and public-float status unchanged month-on-month.